SNIPR Biome’s data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

Avatar photo
Business Intelligence

SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients            SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut            In vitro studies showed SNIPR001 displaying high specificity towards E. coli and activity in multi-drug resistant strains

COPENHAGEN, Denmark, May 5, 2023 /PRNewswire/ —  SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces today that Nature Biotechnology has published research findings from its preclinical work on  SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract.

The emergence of antibiotic-resistant pathogens represents a major global challenge. In numerous disease areas, current medical practice relies on increasingly aggressive therapies, which can sometimes result in patients experiencing life-threatening infections, including those caused by antibiotic-resistant bacteria. This issue is often under-recognized in contemporary healthcare ecosystems and the escalating threat of antimicrobial resistance has the potential to lead to a significant health care challenge in the future.

SNIPR001’s mechanism of action, as a CRISPR-armed phage therapeutic that specifically targets and eradicates E. coli in the gut, is designed to prevent infections from spreading into the bloodstream and represents a promising advancement against antibiotic-resistant pathogens. This publication represents a significant validation of the ground-breaking technology research done at the laboratories and collaborators of SNIPR Biome and also opens up the possibility of targeting other pathogens.

Dr Christian Grøndahl CEO and co-founder of SNIPR Biome, commented: “This therapy has the potential to revolutionize the way we prevent and treat infections, and we believe it could potentially serve as a model for developing similar therapies that target other life-threatening pathogens. By integrating different aspects of drug development, from bioinformatics to regulatory requirements, we have been able to leverage our CRISPR-Cas technology to generate a whole new class of drugs.”

 Dr Eric van der Helm VP of Scientific Affairs of SNIPR Biome, commented:  “This article represents a true team effort over the last few years of many of our employees and collaborators to integrate all aspects of drug development ranging from bioinformatics, synthetic biology, in vitro assays, in vivo models to regulatory requirements and CMC. With more than a million deaths annually attributed to antimicrobial resistance, we are committed to developing precision medicines that will make a significant impact in the fight against this global health threat.”

 SNIPR001 has been granted a Fast-Track designation by the US Food and Drug Administration (“FDA”), was supported by CARB-X, and SNIPR is currently conducting a Phase 1 trial in the US to evaluate its safety and efficacy in reducing E. coli in the gut without disturbing the overall gut microbiome (NCT05277350).

Article citation: Gencay, Y.E., Jasinskytė, D., Robert, C. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nat Biotechnol (2023). https://www.nature.com/articles/s41587-023-01759-y

CONTACT:

SNIPR Biome
Dr Christian Grøndahl, Co-founder and CEO
E-mail: [email protected] 
Mobile: +45 20202747 
www.sniprbiome.com 
Please follow us on LinkedIn & Twitter: @SNIPRBiome

Consilium Strategic Communications
Tracy Cheung, Chris Welsh, Davide Salvi
Tel: +44 (0) 203 709 5700
[email protected]

View original content:https://www.prnewswire.com/apac/news-releases/snipr-biomes-data-on-first-clinical-drug-candidate-to-prevent-infections-in-hematological-cancer-patients-published-in-nature-biotechnology-301816381.html

SOURCE SNIPR Biome ApS

相關文章

李偉農稱澳門經濟適度多元策略為中葡企業提供機遇

澳門經濟財政司司長李偉農在今日開幕的中國—葡語國家經貿合作論壇(澳門)第六屆部長級會議企業家大會上表示,澳門的經濟適度多元發展策略將為中葡企業提供更多發展機遇。

【時事評論】投資多元化!

3月初,隨著北京人民大會堂燈光逐漸暗淡,赴京出席“兩會”的代表們踏上了返程的旅途。“兩會”明確提出澳門特區在國家發展大局中承擔的責任,並旋即在媒體中引起共鳴:有效落實並加快城市經濟適度多元發展,與澳門特別行政區近年來反復強調的經濟政策不謀而合。

【息息相關】無人機任務

一名本地工程師有份創立的科技新創企業正著手推出自動駕駛無人機解決方案,協助本地建築工程完成檢測檢驗任務。這項創新方案將為娛樂場綜合度假村、老化或破舊物業等不同類型的建築提供一個更安全、更有效且更具成本效益的檢測替代方式。 

澳門大學預測2024年澳門GDP增長16.8%

澳門大學發表2024年澳門宏觀經濟修訂預測,預計澳門今年地區生產總值增長16.8%,恢復至2019年水平的94.5%。

澳門2月新批核住宅按揭及商用物業貸款均下跌

澳門金融管理局4月11日發佈的統計數據顯示,2024年2月新批核的住宅按揭貸款按月下跌 42.5%至 6.9 億澳門元。

第十二屆旅博會將於4月26日揭幕

第十二屆澳門國際旅遊(產業)博覽會將於4月26日至28日舉行,今屆旅博會以“相匯旅博 相聚商機”為口號,招聚海內外旅遊及相關業者來澳參與。截至目前,參展商有超過600家,買家約500位,展位超過1,300個。